Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/18—Sulfonamides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
  • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
  • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
  • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

• This invention relates generally to the management of pain, and more particularly relates to methods and compositions for the treatment of pain using a eutectic mixture of a capsaicinoid analgesic and a second drug that mitigates the side effects associated therewith.
• Pain is a significant and costly healthcare problem, and is the most common reason patients seek medical care. Pain may be acute or chronic. Examples of acute pain include post-surgical pain and pain due to traumatic injuries. Chronic pain is generally more difficult to treat, and can be associated with any number of causes. For example, chronic pain may be associated with the inflammation of joints, tendons, nerves, muscle, and other soft tissues, with diseases such as cancer, or with injuries to the nervous system (“neuropathic” pain).
• neuropathic pain is a challenging medical condition to treat as it can involve both the peripheral and central nervous systems.
• Neuropathic pain often persists following viral infection, trauma, administration of certain medications, or a metabolic insult. Nerves that remain intact following such as disease or injury can become hyperactive, causing pain even in the absence of a direct stimulus.
• Neuropathic pain is often described as a burning, excruciating pain and may never resolve. The severity of the pain is in part due to the nerve endings near the surface of the skin.
• neuropathic pain is generally insensitive to administration nonsteroidal anti-inflammatory drugs, which are often successfully prescribed for the treatment of acute pain.
• neuropathic pain There are several types of neuropathic pain. The more common types include post-herpetic neuralgia, neuropathic pain related to human immunodeficiency virus (HIV)—associated neuropathy, neuropathic pain associated with diabetic neuropathy, and trigeminal neuralgia.
• Post-herpetic neuralgia is chronic, mild to severe burning pain on the surface of the skin that develops in some patients after healing of shingles (herpes zoster). Both the HIV infection, as well as HIV medications, are associated with the development of neuropathy and neuropathic pain. This pain typically affects the feet and hands, and is commonly referred to as neuropathic pain related to HIV-associated neuropathy.
• Diabetic neuropathy is a common complication of diabetes mellitus, and can lead to amputation.
• Peripheral diabetic neuropathy is typically characterized by pain, weakness, and reduced or lost sensation in the feet.
• Trigeminal neuralgia is a disorder of the trigeminal nerve, which causes episodes of intense, stabbing, electric shock-like pain in the areas of the face in which nerve endings are located (e.g., the lips, eyes, nose, scalp, forehead, upper jaw, and lower jaw).
• Other types of diabetic neuropathy include autonomic neuropathy, proximal neuropathy, and focal neuropathy.
• neuropathic pain In addition to these common types of neuropathic pain, there are numerous medical conditions that are associated with neuropathic pain. These include traumatic nerve injury, stroke, multiple sclerosis, epilepsy, spinal cord injury, and cancer.
• Capsaicin (8-methyl-N-vanillyl-6Z-nonenamide) and “synthetic” capsaicin (N-vanillyl-nonenamide) are disclosed as analgesics in U.S. Pat. No. 4,313,958 to LaHann. Analgesic activity of capsaicin has also been discussed in the chemical and medical literature, including Yaksh, et al. (1979) Science 206:481-483. Capsaicin is derived from the plants of the solanaceae family, and is the purified extracted alkaloid from red chili peppers.
• Capsaicin has been found to relieve pain by reducing substance P, which is found at nerve endings and is involved in transmitting neuralgic and arthritic pain signals to the brain. Pain relief is not instantaneous after application as it is the cumulative depletion of substance P over a period of weeks that brings the full effect.
• capsaicin topical creams have been used for years to treat neuropathic pain, but their use has been limited because they are inconvenient to apply and must be applied at regular intervals throughout the day, even then achieving only modest pain relief at best.
• capsaicin is a potent skin irritant, and the application of capsaicin itself can cause burning pain and hyperalgesia, exacerbating the pain being treated.
• This intense initial burning effect usually diminishes after the first few days of application and in most cases disappears with time and continued use; the initial side effects are sufficiently severe, however, to significantly impact on patient compliance, thus diminishing the overall therapeutic value of capsaicin as an effective treatment for pain.
• capsaicin formulations In order to minimize the initial burning sensation associated with the topical administration of capsaicin formulations, the skin can be pre-treated with an anesthetic agent. Two-step therapy can be cumbersome for chronic users, however. Furthermore, because capsaicin is poorly soluble in aqueous solvents, any capsaicin formulation used in this context will have a relatively low concentration of the drug, again requiring frequent application as noted above.
• U.S. Pat. No. 4,812,446 to Brand describes an analgesic composition comprising capsaicin or a capsaicin analogue and an analgesic selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic drugs.
• U.S. Pat. No. 4,997,853 to Bernstein describes a 0.01-1.0 wt % capsaicin formulation containing 0.5-25 wt % of a topical anesthetic.
• U.S. Pat. No. 5,962,532 to Campbell et al. describes the use of a 0.01-10 wt % capsaicin formulation to treat pain.
• Anesthesia is first provided to the site where the capsaicin is to be administered, for example, by epidural regional anesthesia.
• U.S. Pat. No. 6,248,788 to Robbins et al. describes a 5-10 wt % capsaicin formulation, accompanied by a regional anesthetic, preferably by means of a somatic or neuraxial block. See also, Robbins et al. (1998) Anesth. Analg. 86:579-583.
• U.S. Pat. No. 5,869,533 to Holt describes a polymeric formulation of 0.00125-1 wt % capsaicin together with a plant extract to neutralize the discomfort resulting from the application of capsaicin.
• U.S. Pat. No. 6,299,902 to Jun et al. describes a two-phase liquid composition comprising a local anesthetic agent, a first melting point depressing agent, for example capsaicin, and a second melting point depressing agent, which is a liquid, more specifically an alcohol.
• An ideal formulation particularly for the treatment of neuropathic pain, would contain higher levels of capsaicin than previously possible but not cause the discomfort and burning associated with capsaicin formulations of the prior art.
• the present invention is directed to the aforementioned need in the art, and provides novel compositions and methods for the treatment of pain, including but not limited to neuropathic pain.
• the invention provides a therapeutic formulation for the treatment of pain wherein the formulation comprises a substantially nonaqueous binary eutectic mixture of active agents that are both solid at 25° C.
• the first active agent is a capsaicinoid having the structure of formula (I) wherein R 1 is hydrogen, hydroxyl or methoxy, R 2 is hydroxyl or C 2 -C 6 alkoxycarbonyl, X is selected from and R is selected from C 5 -C 11 alkyl, C 5 -C 11 alkenyl, C 11 -C 23 cis-alkenyl, C 11 -C 23 alkynyl, and C 11 -C 23 alkadienyl.
• the second active agent is one that is effective to decrease at least one side effect associated with capsaicin monotherapy, and may be a local anesthetic agent or an anti-pruritic agent.
• a therapeutic formulation for the treatment of pain comprises a substantially nonaqueous ternary eutectic mixture of active agents that are all solid at 25° C.
• the first active agent is a capsaicinoid
• the second active agent is a local anesthetic agent
• the third active agent is an anti-pruritic agent.
• a method for treating a patient suffering from pain by administering a therapeutically effective amount of a formulation of the invention to the patient.
• the pain may be neuropathic pain, as may be associated with HIV or diabetic neuropathy.
• alkyl refers to a branched or unbranched saturated hydrocarbon group typically although not necessarily containing 1 to about 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl, and the like. If not otherwise indicated, the term “alkyl” includes linear, branched, cyclic, unsubstituted, substituted, and/or heteroatom-containing alkyl.
• alkenyl refers to a linear, branched or cyclic hydrocarbon group of 2 to about 24 carbon atoms containing at least one double bond, such as ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, tetracosenyl, and the like. If not otherwise indicated, the term “alkenyl” includes linear, branched, cyclic, unsubstituted, substituted, and/or heteroatom-containing alkenyl.
• alkynyl refers to a linear or branched hydrocarbon group of 2 to 24 carbon atoms containing at least one triple bond, such as ethynyl, n-propynyl, and the like. If not otherwise indicated, the term “alkynyl” includes linear, branched, cyclic, unsubstituted, substituted, and/or heteroatom-containing alkynyl.
• treating and “treatment” as used herein refer to reduction in severity and/or frequency of pain, elimination of pain, prevention of pain, and/or prevention of pain.
• an effective amount and “therapeutically effective amount” of a formulation of the invention is meant a nontoxic but sufficient amount of the formulation to provide the desired effect.
• the amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agents. and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
• a therapeutically effective amount of capsaicin is that quantity needed to treat or prevent pain, e.g., neuropathic pain.
• a therapeutically effective amount of an anesthetic agent is that concentration needed to prevent burning or discomfort from capsaicin at the site of administration.
• pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
• pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
• “Pharmacologically active” or simply “active” as in a “pharmacologically active” derivative or analog, refers to a derivative or analog having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
• a therapeutic formulation is provided that is substantially nonaqueous, i.e., contains less than 5 wt. %, preferably less than 2.5 wt. %, and most preferably less than 1 wt. % water, and is composed of a binary eutectic mixture of a capsaicinoid and a second active agent.
• binary eutectic mixture refers to a mixture of two components that has a melting point that lower than the melting point of either component. In the present context, the two components of the binary eutectic mixture are solid at 25° C. but the eutectic mixture itself is preferably a liquid at 25° C.
• capsaicinoid refers to an analgesic agent, generally used as a topical analgesic agent, having the structure of formula (I) wherein R 1 is hydrogen, hydroxyl or methoxy, R 2 is hydroxyl or C 2 -C 6 alkoxycarbonyl, X is selected from and R is selected from C 5 -C 11 alkyl, C 5 -C 11 alkenyl, C 11 -C 23 cis-alkenyl, C 11 -C 23 alkynyl, and C 11 -C 23 alkadienyl.
• R 1 is hydrogen, hydroxyl or methoxy
• R 2 is hydroxyl or C 2 -C 6 alkoxycarbonyl
• X is selected from and R is selected from C 5 -C 11 alkyl, C 5 -C 11 alkenyl, C 11 -C 23 cis-alkenyl, C 11 -C 23 alkynyl, and C 11 -C 23 alkadienyl.
• the capsaicinoid is selected from resiniferatoxin, N-vanillyl-alkadienamides, N-vanillyl-alkanedienyls, N-vanillyl-monounsaturated alkenamides, N-vanillylsulfonamides, and hydroxyphenylacetamides.
• the capsaicinoid is an N-vanillyl-monounsaturated alkenamide (i.e., R 1 is methoxy, R 2 is hydroxyl, X is —NH—(CO)—, and R is an alkene chain), and in a particularly preferred embodiment, the N-vanillyl-monounsaturated alkenamide is capsaicin (R is —(CH 2 ) 4 —CH ⁇ CH—CH(CH 3 ) 2 ).
• the second active agent may be a local anesthetic agent that can alleviate the pain and discomfort associated with capsaicin monotherapy (i.e., administration of capsaicin without a second active agent) or may be an anti-pruritic agent, which can alleviate the itching and irritation associated with administration of capsaicin.
• Any local anesthetic agent or anti-pruritic agent that is a solid at 25° C. can be used in the formulations of the invention.
• the term “solid” is intended to include hygroscopic compounds and other solids that, under certain conditions, take a semisolid form.
• the local anesthetic agent is a drug that provides local numbness or pain relief by producing a reversible loss of sensation by inhibiting or by decreasing pain at the site of application, without resulting in a loss of nerve control.
• Representative local anesthetic agents include amylocaine, articaine, benzocaine, bupivacaine, butacaine, 2-chloroprocaine, cinchocaine, dexivacaine, diamocaine, dibucaine, etidocaine, ketocaine, lidocaine, mepivacaine, oxybuprocaine, parethoxycaine, prilocaine, procaine, propanocaine, proparacaine, propoxycaine, pyrrocaine, risocaine, rodocaine, ropivacaine, tetracaine, and combinations thereof.
• Preferred local anesthetic agents for use in the present formulations are lidocaine and tetracaine.
• anti-pruritic agents include, by way of illustration and not limitation, camphor, phenol, and menthol.
• the active agents may be incorporated into the formulation in the form of a salt, ester, amide, prodrug, active metabolite, analog, or the like, provided that the salt, ester, amide, prodrug, active metabolite, or analog is pharmaceutically acceptable and pharmacologically active in the present context.
• Salts, esters, amides, prodrugs, active metabolites, analogs, and other derivatives of the active agents may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992).
• the free base form of the local anesthetic agent is used since, typically, the free base form has a lower melting point than the equivalent salt.
• the binary eutectic mixture enables incorporation of the capsaicinoid into the formulation at higher levels than previously possible.
• the capsaicinoid represents about 10 wt. % to about 70 wt. % of the formulation, preferably about 40 wt. % to about 70 wt. % of the formulation.
• the formulation is substantially free of components other than the two active agents (i.e., the active agents represent at least 90 wt. % of the formulation, preferably at least 95 wt. % of the formulation, and optimally at least 99 wt. % of the formulation), and therefore does not contain carriers, excipients, enhancers, or other additives.
• a therapeutic formulation is provided that is composed of a capsaicinoid having the structure of formula (I) and two additional active agents, wherein the formulation is substantially nonaqueous as defined above.
• Each of the two additional active agents is effective to decrease at least one side effect associated with capsaicin monotherapy, e.g., pain, discomfort, itching, or irritation.
• one of the additional active agents is a local anesthetic agent as described above, and the other of the additional active agents is an anti-pruritic agent as also described above.
• Preferred capsaicinoids are N-vanillyl-monounsaturated alkenamides, with capsaicin per se particularly preferred.
• the capsaicinoid generally, although not necessarily, represents about 10 wt. % to about 50 wt. % of the formulation, with the two active agents together representing about 50 wt. % to about 90 wt. % of the formulation.
• the weight ratio of the two additional active agents e.g., the local anesthetic agent and the anti-pruritic agent, is approximately 1:1.
• the three active agents, the capsaicinoid, the local anesthetic agent, and the anti-pruritic agent will be in an approximately 10:45:45 to 50:25:25 ratio by weight.
• the solid components are mixed together. After about 30 minutes, a moist mixture is formed, and subsequently, for example over a 24-hour period, a liquid is formed and the ingredients remain in the liquid state.
• the mixture may be warmed to expedite formation of the liquid, although this is not required.
• the formulations of the invention are primarily or even entirely composed of active agents, and furthermore because the capsaicinoid represents a substantial fraction of the formulation, extremely high doses of the capsaicinoid can be delivered with a relatively small amount of the formulation.
• the incorporation of the additional active agents, e.g., the local anesthetic agent and/or the anti-pruritic agent, will facilitate patient compliance since the side effects of capsaicin are substantially reduced.
• there is no need to further formulate the capsaicin into cream or gel because the liquid can be packaged as is, for example, in a “roll-on” type applicator.
• the formulations of the invention find utility in pain caused by inflammation of joints, tendons, nerves, muscle, and other soft tissues, including arthritic pain; back pain; headache pain; pain caused by cancer; and neuropathic pain, the latter of which is of particular interest.
• neuropathic pain for which the formulations of the invention are particularly well-suited, include, post-herpetic neuralgia, neuropathic pain related to HIV-associated neuropathy, pain associated with diabetic neuropathy, and neuropathic pain associated with trigeminal neuralgia.
• Administration of a formulation of the invention may be carried out using any appropriate mode of administration. Typically, administration will be carried out topically rather than systemically, although systemic administration, generally parenteral administration, is possible.
• Capsaicin (“Cap”) and lidocaine (“Lido”) were mixed in the various ratios set forth in Table 1. Some of the formulations spontaneously became partially liquid. All of the formulations were mildly heated to form a uniform solution. The solutions were allowed to crystallize and/or separate at room temperature. The mixtures were also analyzed by DSC.
• Capsaicin, menthol, and lidocaine were mixed in the ratios given in Table 2. As in Example 1, some of the formulations spontaneously became partially liquid. All of the formulations were mildly heated to form a uniform solution. The solutions were allowed to crystallize and/or separate at room temperature.
• Capsaicin (“Cap”) and tetracaine (“Tetra”) were mixed in the ratios set forth in Table 3. As in Example 1, some of the formulations spontaneously became partially liquid. All of the formulations were mildly heated to form a uniform solution. The solutions were allowed to crystallize and/or separate at room temperature. TABLE 3 Observations Composition Melt/ Cap:Tetra Immediately 24 hours (over 2 weeks) 100 Solid Solid Solid 10:90 Solid Wet mass Liquid 30:70 Solid Wet mass Liquid 40:60 Wet mass Wet mass Liquid 50:50 Wet mass Wet mass Liquid 60:40 Wet mass Wet mass Wet mass 70:30 Wet mass Wet mass Wet mass 90:10 Wet mass Wet mass Wet mass
• Capsaicin (“Cap”) and menthol were mixed in the different ratios set forth in Table 4. Some of the formulations spontaneously became partially liquid. All of the formulations were mildly heated to form a uniform solution. The solutions were allowed to crystallize and/or separate at room temperature.

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=34993266

Family Applications (4)

Family Applications After (3)

Country Status (7)

Cited By (19)

Families Citing this family (10)

Citations (3)

Family Cites Families (23)

• 2005
  • 2005-06-02 ES ES05758668.7T patent/ES2542847T3/es active Active
  • 2005-06-02 EP EP20050758668 patent/EP1763370B1/fr not_active Not-in-force
  • 2005-06-02 AU AU2005249572A patent/AU2005249572A1/en not_active Abandoned
  • 2005-06-02 JP JP2007515650A patent/JP5148271B2/ja not_active Expired - Fee Related
  • 2005-06-02 WO PCT/US2005/019687 patent/WO2005117981A1/fr active Application Filing
  • 2005-06-02 US US11/145,266 patent/US20060100272A1/en not_active Abandoned
  • 2005-06-02 CA CA002569155A patent/CA2569155A1/fr not_active Abandoned
• 2011
  • 2011-09-14 US US13/232,905 patent/US8889736B2/en not_active Expired - Fee Related
• 2014
  • 2014-10-17 US US14/517,603 patent/US20150250745A1/en not_active Abandoned
• 2018
  • 2018-08-20 US US15/999,705 patent/US10576047B2/en not_active Expired - Fee Related

Patent Citations (3)

Also Published As

Similar Documents

Legal Events